38 results about "Schizophrenia" patented technology

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The invention discloses a mental disease brain dysfunction detection method based on dynamic causal modeling, and belongs to the field of biomedical engineering. The dynamic causal relationship of information transmission among regions of the brain can be accurately captured by adopting dynamic causal modeling based on electroencephalogram, and the method has unique advantages in the aspect of revealing abnormal modes of mental disease information transmission. Different from a traditional functional brain network construction mode, the system pays more attention to capturing the causal relationship and dynamic change of brain intervals when processing and explaining data, the modeling method based on the causal relationship can provide more detailed and personalized information transmission analysis to a certain extent, a more accurate result is provided, and the method is suitable for popularization and application. Furthermore, the functional disorder in the mental disease brain neural network can be sensitively recognized, the pathological mechanisms of bipolar affective disorder, schizophrenia and split affective disorder can be revealed, and support is provided for early diagnosis and personalized treatment.

The invention provides a schizophrenia early recognition and risk prediction method and system based on multi-mode speech analysis, and belongs to the technical field of medical artificial intelligence. The method comprises the following steps: prospectively acquiring natural voice data of an individual in a clinical high-risk period, performing clinical follow-up visit for two years, and constructing a first Chinese schizophrenia clinical high-risk voice longitudinal data set; based on the data set, audio and text features in the voice are extracted, a layered multi-mode integrated model is constructed, semantic coherence and acoustic features are fused, and early prediction of the schizophrenia transformation risk is achieved; through feature importance analysis, key voice marks closely related to negative symptoms, thinking disorder and cognitive impairment are recognized, and non-invasive, accurate and interpretable early recognition is achieved. According to the method, the technical blank of early screening tools for schizophrenia in Chinese context is filled, and the accuracy and stability of early recognition are remarkably improved.

The invention provides a traditional Chinese medicine formula for treating schizophrenia, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine formula for treating schizophrenia comprises the following medicinal materials: gypsum, pig iron, amur skullcap root, ossa draconis, callicarpa bodinieri, buffalo horn, coptis root, baical skullcap root, amur corktree bark, turmeric root-tuber, aloe, suberect spatholobus stem, costus root, Chinese angelica, officinal magnolia bark, elephantopus scaber, rhubarb, mirabilite and the like. A decoction method comprises the following steps: firstly decocting part of the medicinal materials for 40 minutes, then adding the rest of the medicinal materials, decocting for 30 minutes, decocting for three times, mixing, and taking in three times, so as to solve the problems of large side effect, strong dependence, slow effect and the like in the existing treatment method. The traditional Chinese medicine composition has the beneficial effects of relieving side effects, reducing dependency and drug resistance, relatively fast effect taking, relatively stable treatment effect, comprehensive conditioning and the like, various medicinal materials are synergistic, and the effects of clearing heat, purging fire, relieving convulsion, soothing the nerves, promoting qi circulation, relieving depression, activating blood, enriching blood and the like are achieved, so that the symptoms of schizophrenia patients are relieved, and the treatment effect is improved.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention provides a method and device for generating information based on brain image data, and the method comprises the steps: carrying out the longitudinal brain image analysis of the brain image data, collected at multiple time points, of a target individual, carrying out regional division on the brain of the target individual at each time point and extracting morphological measurement values of each region based on a longitudinal brain image analysis result and a cortex partition map; based on the brain form norm, the deviation degree of the morphological measurement value of each region of the brain of the target individual at each time point relative to the brain form norm is determined, and the individual brain form deviation vector corresponding to the target individual at each time point is obtained; performing correlation calculation on the individual brain form deviation vector corresponding to the target individual at each time point and the statistical data of the plurality of mental diseases in the whole brain range to obtain cross-disease brain form similarity features; and inputting the cross-disease brain form similarity features into a pre-trained machine learning model, and outputting classification information about whether the target individual is a schizophrenia patient or not, and / or prediction information about clinical indexes.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The present invention relates to a novel compound as a 5-HT 2A receptor inverse agonist, a method for preparing the same and a pharmaceutical composition. It also relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating 5-HT 2A receptor related diseases, including non-motor symptoms of Parkinson's disease: delusions, hallucinations, depression, anxiety, cognitive impairment, sleep disorders; dementia-related psychiatric disorders; major depressive disorder; or negative symptoms of schizophrenia, etc.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating / preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

The invention provides an experimental method for verifying the curative effect of retinoic acid on schizophrenia, which comprises the following steps: step 1, selecting two groups of pregnant SD rats, injecting Poly I: C into tail veins of one group of SD rats after 9.5 days of pregnancy according to the standard of 10 mg / kg, and taking male offspring rats as schizophrenia model group rats; the other group of SD rats are intravenously injected with equal-volume normal saline at the tail after pregnancy 9.5 days, and the male offspring rats are the control group; 2, the model components are divided into two groups, retinoic acid is fed to one group 45 days after birth according to the standard of 3 mg / kg / day, an equal amount of placebo is injected to the other group, and an equal amount of placebo is injected to the control group; step 3, carrying out behavioral detection experiments on the three groups of rats in the step 2; and 4, implanting electrodes into hippocampal CA1 regions of the three groups of rats in the step 2, and recording and analyzing electroencephalogram activities of the three groups of rats. The experimental method provided by the invention proves that the retinoic acid has good application value in preparation of the schizophrenia medicine.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention discloses a schizophrenia typing method based on delta wave band fractal dimension individual heterogeneity, and belongs to the technical field of neural information processing and mental disease auxiliary diagnosis. According to the method, firstly, innovation is achieved in the aspect of frequency band specificity analysis, feature extraction can be carried out on the schizophrenia key information processing frequency band, and disease abnormity can be captured more sensitively. And secondly, the site effect of cross-center data acquisition is effectively coordinated by introducing a ComBat method, and the modeling stability and the result reliability are improved. Thirdly, a standardized model is obtained through multi-center large sample training, individualized deviation modeling is further carried out, the abnormal degree of a single patient relative to a healthy group can be accurately described, and the limitation of traditional group mean value comparison is broken through. Afterwards, in combination with a hierarchical heterogeneity analysis method based on discriminant analysis, stage identification and potential subtype division of the disease are realized, so that the method has a refined typing capability.

The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditions caused by physiological processes implicating the orphan receptor GPR88, including diverse brain and behavioral functions such as cognition, mood, movement control, and reward-based learning. GPR88 is emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. One particular indication for which GPR88 agonists hold promise is alcohol use disorder (AUD).

A C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2-Leap1 decoupling agent, and a use of the compound in the preparation of a medicament for preventing and / or treating diseases in a patient, the diseases comprising cerebral small vessel disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, cognitive impairment in schizophrenia, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

This invention discloses a submillimeter-level diffusion magnetic resonance imaging (DTI) method for extracting the radial index of cortical layered cognitive structures, relating to the field of medical image processing technology. This invention aims to address the problems of existing technologies failing to accurately quantify the directionality of cortical microstructures and neglecting the heterogeneity of cortical layering. The method includes: acquiring DTI data and performing high-fidelity preprocessing such as MP-PCA denoising, Gibbs artifact removal, and Gaussian process distortion correction; estimating the diffusion tensor and extracting the principal feature vector based on the preprocessed data; reconstructing the cortical white matter and pia mater surface using T1 images and extracting the normal vector; calculating the absolute value of the dot product of the diffusion principal feature vector and the surface normal vector to construct a radial index map; and segmenting the cortex into multiple intermediate layers based on the principle of equal volume and extracting layering parameters. Through refined high-resolution data processing and geometric modeling, this invention can accurately quantify the radial alignment integrity of cortical nerve fibers, providing highly sensitive imaging markers for cognitive disorders such as schizophrenia.

The invention discloses a method for evaluating the recovery benefit of a giant panda national park greenway on a refined patient. The method comprises the following steps: acquiring an image of the giant panda national park greenway; preprocessing the giant panda national park greenway image; selecting a sperm fraction patient subject; obtaining the recovery benefit of the perceptual classification patient subject on the greenway image of the giant panda national park by adopting a perceptual recovery scale; screening environmental factors in the giant panda national park greenway image; quantifying environmental factors in the giant panda national park greenway image; and constructing a correlation prediction model between the environment characteristic factors and the scores of the perception recovery scale. According to the method, environment feature factors are quantified through images, greenway environment features are systematically analyzed, the association prediction model is constructed, dynamic association between environment elements and rehabilitation indexes of the precisely-classified patient is revealed, and a new data-driven normal form is provided for scientific design of the rehabilitation-oriented greenway.

The invention discloses a method and system for constructing a schizophrenia symptom severity prediction model, and relates to the field of disease auxiliary diagnosis, and the method comprises the steps: obtaining historical electroencephalogram data of a patient, and constructing a weighted undirected connection matrix; obtaining a plurality of key graph theory indexes based on the weighted undirected connection matrix in combination with a graph theory algorithm; wherein the plurality of key graph theory indexes comprise a clustering coefficient, a path length, global efficiency and local efficiency; taking the plurality of obtained key graph theory indexes as predictive factors, and inputting the predictive factors and the dependent variable PANSS score into a constructed multiple linear regression model to determine a linear relationship between the plurality of key graph theory indexes and the dependent variable PANSS score; and obtaining a schizophrenia symptom severity prediction model for predicting the symptom severity of the schizophrenia patient according to the linear relationship between the plurality of key graph theory indexes and the PANSS score.

A method of predicting brain age for a subject having a mental health condition. The method comprises obtaining at least one medical image of a brain of a subject; preprocessing the medical image to produce a brain map; segmenting the brain map into more than one brain regions; and calculating a brain age of the subject based on a predetermined set of key features for each of the brain regions.

The present invention relates to the compound 4-(6-oxo-2-(trifluoromethyl)-3,6- dihydrochromeno[7,8-d]imidazol-8-yl)benzonitrile, also known as CF3CN, referred to herein as the compound of Formula I, for use in the treatment of positive symptoms in schizophrenia.

This invention discloses a method and system for assessing cognitive function in mental disorders based on attention mechanisms, belonging to the field of mental disorder assessment technology. The method includes: acquiring multi-channel EEG signals of subjects under an adaptive dual-task paradigm; performing time-frequency analysis to extract frequency bands and instantaneous power time-series features of the frequency bands; inputting the features into a pre-trained game-theoretic attention network to calculate the dynamic game-theoretic coupling strength between the network and oscillations, generating a game equilibrium deviation time-series sequence; extracting an imbalance threshold index and a compensation cost index from the sequence; and inputting the index into a classifier to generate a cognitive function assessment index. This invention analyzes the dynamic game-theoretic relationship between oscillations through attention mechanisms, quantifying the degree of imbalance in attention resource allocation in multi-task competitive scenarios for patients with schizophrenia. It exhibits high sensitivity and specificity, providing an objective and quantitative tool for assessing cognitive impairment in mental disorders.

The invention relates to a novel application of gliclazide, in particular to an application of gliclazide or pharmaceutically acceptable salt thereof in preparation of medicines for preventing and / or treating symptoms of psychosis. Wherein psychotic symptoms are generally related to schizophrenia and other diseases which may use antipsychotic drugs, including delusional, hallusion, thinking / speech disorder, agitation, obvious disorder or abnormal motor behavior (including tension), irritability and the like.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the 5-HT4 receptor agonist in the manufacture of medicament intended for the treatment of the disorders described herein.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

Provided herein are methods of ameliorating experiential negative symptoms of schizophrenia in a user in need thereof. A computing system may obtain a first metric associated with the user prior to a plurality of time instances. The computing system may repeat across a plurality of time instances, identifying a configuration file selected based on an endpoint for ameliorating the experiential negative symptoms. The computing system may repeat presenting the set of content items identified by the configuration file to prompt the user to perform the activity towards achieving the endpoint. The computing system may obtain a second metric associated with the user after the plurality of time instances. The user may show amelioration of experiential negative symptoms of schizophrenia, when the second metric is lower than the first metric. The computing system may increase the efficacy of the medication that the user is taking to address the schizophrenia.